Abstract: Compounds of the formula ##STR1## wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.

Abstract: A stable oral rinse or clear oral gel composition, comprising:a) about 0.01% by weight to about 1% by weight of hydrated zinc cations;b) about 0.01% by weight to about 4% by weight of fully or partially protonated citrate moieties;c) about 0.01% by weight to about 2% by weight of cetyl pyridinium cations; andd) an orally acceptable vehicle;wherein said composition has a pH of from about 3.0 to about 4.5.

Abstract: Oral rinse and dentifrice compositions, comprising a phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; and a cyclodextrin selected from the group consisting of hydroxypropyl .beta.-cyclodextrin, hydroxyethyl .beta.-cyclodextrin, hydroxypropyl .gamma.-cyclodextrin, hydroxyethyl .gamma.-cyclodextrin, .alpha.-cyclodextrin, methyl .beta.-cyclodextrin, and mixtures thereof. These compositions are useful in retarding the development of plaque, treating gingivitis, and in treating the presence of micro-organisms in the oral cavity.

Abstract: An oral rinse, dentifrice, or oral gel composition comprising:a) about 0.01 weight % to about 5 weight % of a citrus flavor, citrus flavor ingredient, or mixtures thereof;b) about 0.01 weight % to about 5 weight % of a phenolic, said phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof; andc) an orally acceptable carrier.The claimed composition is useful in retarding the development of plaque, treating gingivitis, and reducing the viable population of micro-organisms in the oral cavity of a mammal.

Abstract: Compounds of the formula ##STR1## wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.

Abstract: A composition useful in the treatment of onychomycosis comprises tioconazole, a gel-forming agent and a hydro-alcoholic vehicle.

Abstract: A compound of formula (I): ##STR1## and the pharmaceutically acceptable base salts thereof, wherein: R is CO.sub.2 R.sup.12 where R.sup.12 is H or a biolabile ester-forming group, or R is tetrazol-5-yl, and either (a) R.sup.1 is ##STR2## and R.sup.2 is F, Cl, Br, I, CH.sub.3 or CF.sub.3, or (b) R.sup.1 is C.sub.3 -C.sub.6 alkyl and R.sup.2 is C.sub.2 -C.sub.4 alkyl, useful as steroid 5-.alpha.-reductase inhibitors.

Abstract: A post-foaming gel shaving composition is disclosed which contains from about 40 to about 90 percent by weight water; from about 4 to about 25 percent by weight water-soluble soap; from about 0.5 to about 12 percent by weight aliphatic liquid post-foaming agent selected from the group consisting of saturated aliphatic hydrocarbons; from about 0.01 to about 5 percent by weight of at least one water-soluble gelling agent forming in said composition a gel having a yield value sufficiently high to restrain said composition from foaming for at least about 60 seconds; and from about 0.1 to about 2 percent by weight of a poly(ethylene oxide) having an average molecular weight of at least 2.times.10.sup.5.

Abstract: Compounds of formula (I), wherein R.sub.1 is (a), (b), (c) or (d); n is 0, 1 or 2; A, B, C and D are each independently nitrogen or carbon; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, nitro, --(CH.sub.2).sub.m NR.sub.14 R.sub.15, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.14 R.sub.15, --(CH.sub.2).sub.m NR.sub.14 SO.sub.2 R.sub.15 --(CH.sub.2).sub.m NR.sub.14 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.14 COR.sub.9, --(CH.sub.2).sub.m NR.sub.14 CONHR.sub.9, --CONR.sub.14 R.sub.15, or --CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, or R.sub.4 and R.sub.

Abstract: Tablets of increased strength are manufactured by combining and compressing a meltable binder, excipients and a pharmaceutically active agent into a tablet, melting the binder in the tablet, and then solidifying the binder.

Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.

Abstract: Compounds of formula (I), wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alky, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2 .sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.6 may be taken together to form a 5- to 7-membered alkyl ring, a 6-membered aryl ring, a 5- to 7-membered heteroalkyl ring, having 1 heteroatom of N, O, or S, or a 5- to 6-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R.sub.

Abstract: A fluid dispensing device for use with a fluid reservoir having a cup having a bottom wall and a top wall, the top wall including an orifice to permit removal of fluid from the cup and with the top wall having a threaded axial opening, the bottom wall being coupled to a conduit adapted for communication with fluid in a reservoir; and a column rotatably positioned in the axial opening and extending therefrom into and out of the cup, the column including an orifice positioned in the cup, the column including a threaded portion being cooperative with the threaded axial opening such that the position of the column orifice in the cup can be varied through a vertical range of movement by rotation of the column, and the column further including a tubular portion being in fluid communication with the column orifice and with the conduit and movable relative to the conduit while substantially maintaining a seal therebetween throughout the vertical range of movement of the orifice in the cup.

Abstract: The present invention relates to a topical protein preparation to be used for the therapy of periodontitis and diseases of the teeth and of the tissues of the oral cavity, comprising a mixture of transferrin with at least one protein selected from albumins, lysozymes, protease inhibitors, and mixtures thereof.

Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.

Abstract: The present invention is directed to a topical composition for the treatment of psoriasis. The composition comprises a film forming agent, a plasticizer, an aqueous alcoholic solution and an amount of alkali effective to prevent the gellation of the film forming agent. Vinyl acetate crotonic acid copolymer and poly(vinyl)acetate are especially preferred film-forming agents.

Abstract: Compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates (including hydrates) of either entity, wherein R.sup.1 is (a) R.sup.2 is R.sup.3 R.sup.4 C(OH)A; V is C.dbd.O or CH.sub.2 ; W is O or NR.sup.5 ; R.sup.3 and R.sup.4 are each independently selected from H and C.sub.1 -C.sub.4 alkyl; or, together with the carbon atom to which they are attached, form a 4- or 5-membered carbocyclic ring; R.sup.5 is H, benzyl, C.sub.1 -C.sub.5 alkanoyl or SO.sub.2 (C.sub.1 -C.sub.4)alkyl; A is C.sub.2 -C.sub.3 alkylene; m is 0 or 1; and n is 0 or 1; with the provisos that when n is 1 and V is C.dbd.O then W is NH, and when n is 1 and V is CH.sub.2 then W is O; are selective 5-HT.sub.1 -like agonists useful in the treatment of, inter alia, migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders.

Abstract: The Invention provides a process for preparing a compound of the formula: ##STR1## or a base salt thereof, wherein R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl optionally substituted by up to 3 substituents each independently selected from the group consisting of C.sub.1 -C.sub.6 alkoxy and C.sub.1 -C.sub.6 alkoxy(C.sub.1 -C.sub.6 alkoxy)-; and R.sup.3 is C.sub.1 -C.sub.6 alkyl or benzyl, said benzyl group being optionally ring-substituted by up to 2 nitro or C.sub.1 -C.sub.4 alkoxy substituents comprising reacting a compound of the formula: ##STR2## wherein R.sup.1 is C.sub.1 -C.sub.4 alkyl, phenyl or benzyl or C.sub.1 -C.sub.4 alkoxy; and R.sup.2 and R.sup.3 are as previously defined for a compound of the formula (I), with hydrogen peroxide or a source of peroxide ions: said process being optionally followed by conversion of the compound of the formula (I) to a base salt thereof. The present invention also relates to novel compounds of the formula (II).